jRCT1071260043招募中不适用
A Multicenter, Prospective Observational Study to Evaluate the Efficacy and Safety of Mosunetuzumab Plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (W-JHS NHL04, SUNMOSTAR)
未提供0 个研究点目标入组 300 人开始时间: 待定
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients scheduled to receive Mosun+Pola combination therapy as part of routine treatment for relapsed or refractory aggressive B-cell lymphoma, based on the latest electronic package inserts for mosnetuzumab and polatuzumab vedotin.
- •The indications based on the latest electronic package inserts are as follows:
- •Relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high-grade B-cell lymphoma)
- •Relapsed or refractory follicular lymphoma (Grade 3B)
- •Patients who have received sufficient explanation about the content of this study, and have obtained written consent from the patient themselves.
- •Patients aged 18 years or older at the time of obtaining informed consent.
排除标准
- •Patients who meet the following criteria will be excluded from this clinical study:
- •Patients who, in the opinion of the principal investigator or subinvestigator, are not suitable for participation in this study.
研究者
相似试验
尚未招募
不适用
A single-center prospective observational study to evaluate the safety and efficacy of sentinel lymph node navigation surgery (SNNS) for uterine malignanciesEarly-stage cervical cancer and early-stage endometrial cancerjRCT1030260079196
招募中
不适用
A Prospective Comparative Study Evaluating the Effectiveness of a Novel Endoscopic Resection Technique (Tip-in UEMR) for Superficial Duodenal Tumors Measuring 10-20 mmSuperficial non-ampullary duodenal epithelial tumor (SNADET)jRCT105225018376
招募中
4 期
A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of LanifibranorNon-alcoholic steatohepatitis2025-524385-18-00Inventiva30
招募中
不适用
A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)Spinal Muscle AtrophyNCT07531719Hoffmann-La Roche30
招募中
不适用
JBCRG-C14(DAHLIA study) (JBCRG-C14(DAHLIA study))Hormone receptor-positive, HER2-negative, unresectable or recurrent breast cancerjRCT1031250721300